Pharmaceutical

Chinese NMPA approves Innovent and IASO Bio’s myeloma therapy

China has granted approval for Innovent Biologics and IASO Bio Fucaso for treating relapsed or refractory multiple myeloma (RRMM) in adults.

Jul 3, 2023 - 20:00
Chinese NMPA approves Innovent and IASO Bio’s myeloma therapy
China has granted approval for Innovent Biologics and IASO Bio Fucaso for treating relapsed or refractory multiple myeloma (RRMM) in adults.
Read the original article

Tags:

Previous Article

Eli Lilly’s retatrutide sets new record for weight loss in obesity space

Next Article

Madrigal seeks expedited approval for NASH treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Clients bring politics into the therapy room. Here’s what that means for the therapist

Opinion: Clients bring politics into the therapy room. ...

Dec 9, 2023

Who’s in charge of the White House Covid response after the emergency ends?

Who’s in charge of the White House Covid response after...

May 9, 2023

Which drugs are most likely to be approved in Somatic P...

Mar 28, 2024